Re: Boyer et al.: Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema (Ophthalmology 2014;121:1904-14)

Ophthalmology

Volumn 122, Issue 3, 2015, Pages e20-e21

  Ziemssen, Focke ^a   Agostini, Hansjürgen ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; HEMOGLOBIN A1C; ANTIINFLAMMATORY AGENT;

BLOOD PRESSURE; CENTRAL RETINAL THICKNESS; DIABETIC MACULAR EDEMA; DRUG IMPLANT; HUMAN; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; LETTER; METABOLIC REGULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULOPATHY; RETREATMENT; DIABETIC RETINOPATHY; FEMALE; MACULAR EDEMA; MALE;

ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; DIABETIC RETINOPATHY; FEMALE; HUMANS; MACULAR EDEMA; MALE;

EID: 84924054843     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.08.016     Document Type: Letter

References (5)

1. D.S. Boyer, Y.H. Yoon, and R. Belfort Jr. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema Ophthalmology 121 2014 1904 1914
2. M.M. Liu, Y. Wolfson, and S.B. Bressler Comparison of time- and spectral-domain optical coherence tomography in management of diabetic macular edema Invest Ophthalmol Vis Sci 55 2014 1370 1377
3. P. Mitchell, and T.Y. Wong Diabetic Macular Edema Treatment Guideline Working Group. Management paradigms for diabetic macular edema Am J Ophthalmol 157 2014 505 513
4. F. Ziemssen, H. Helbig, and K.D. Lemmen Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists: treatment of diabetic maculopathy (April 2013) Klin Monbl Augenheilkd 230 2013 614 628
5. P. Hooper, M.C. Boucher, and K. Colleaux Contemporary management of diabetic retinopathy in Canada: from guidelines to algorithm guidance Ophthalmologica 231 2014 2 15